# of Displayed Technologies: 6 / 6

Applied Category Filter (Click To Remove): Duchenne Muscular Dystrophy


BELS: Behavior, Emotion, Learning and Social Evaluation
TS-000833 — Psychologist Natalie Truba and Harvard Medical School’s Molly Colvin have developed a new tool to screen and measure the emotional, behavioral, learning, and social needs of pediatric patients diagnosed with Duchenne or Becker muscular dystrophy. Both muscular dystrophies are progressive, inherited disorders that display as muscle weakness that impacts the child’s ability to stand and walk. The intention of the tool is to advise and guide providers who lack direct access to mental health providers during clinic visits. This screening provides recommendations for support, guidance, or for further investigation or intervention for triaging mental, behavioral, or learning concerns.
  • College:
  • Inventors: Truba, Natalie
  • Licensing Officer: Corris, Andrew

AAV-Mediated HITI Gene Editing for Correction of Diverse DMD Mutations in Patients with Muscular Dystrophy
TS-000513 — Dystrophinopathies are a group of disorders caused by mutations in the DMD gene which codes for dystrophin, the vital, muscle-specific structural protein. Currently, there is no cure for muscular dystrophy, and patients only rely on palliative care options. Our gene therapy researchers at Nationwide Children’s Hospital have developed an AAV-mediated gene editing method for correcting deleterious DMD mutations in affected patients. This therapy uses a homology-independent targeted integration (HITI) to replace any missing or aberrant exons in affected patients; therefore, correcting the underlying cause of DMD. This therapy will be developed to stop the progression of muscle wasting and fibrosis in individuals with DMD mutations that result in muscular dystrophy via permanent correct of the underlying cause within muscle tissue by replacing missing or aberrant exons using HITI. Advantages By developing AAV-Mediated HITI gene editing for correction of diverse DMD mutations in patients with muscular dystrophy, we can potentially cure BMD and DMD patients. These patients currently have no palliative care options. Our compositions of matter for this approach (i.e. genomic target region, guide-RNA sequences, donor DNA sequences) are new. Stage of Development Proof of concept studies completed Intellectual Property Provisional Patent Pending
  • College:
  • Inventors: Flanigan, Kevin; Havens, Julian; Stephenson, Anthony
  • Licensing Officer: Eidahl, Jocelyn

AAV-Mediated CRISPR/Cas9 Gene Editing for Correction of DMD Exon Duplications in Patients with Muscular Dystrophy
TS-000438 — Gene therapy experts at Nationwide Children’s have developed an AAV-mediated CRISPR/Cas9 gene editing method for the correction of exon duplications in patients with DMD (Duchenne muscular dystrophy). This therapy has the potential to permanently corrects DMD by stopping and potentially reversing the progression of muscle wasting and fibrosis in affected individuals. Currently about 11% of DMD cases are caused by exon duplications and our experts plan to use this invention to correct for this underlying cause within muscle tissues.
  • College:
  • Inventors: Flanigan, Kevin; Stephenson, Anthony
  • Licensing Officer: Barkett, Margaret

Induction of Dystrophin DelCH2 Isoform
TS-000308 — Absence of the dystrophin protein leads to the severe muscle disorder Duchenne Muscular Dystrophy (DMD). Nearly asymptomatic patients have been identified to produce a functional N-terminal truncated dystrophin protein. Gene therapy experts at Nationwide Children's Hospital are developing a U7-snRNA exon skipping strategy to facilitate expression of a truncated dystrophin protein for patients carrying mutations within exon 6 to 9 of the DMD gene, rendering their dystrophin nonfunctional. Our experts have effectively skipped exon 8 in patient-derived cell lines and in turn produced a functional truncated dystrophin protein product.
  • College:
  • Inventors: Wein, Nicolas; Flanigan, Kevin
  • Licensing Officer: Eidahl, Jocelyn

A Novel Mouse Model of Duchenne Muscular Dystrophy with a Duplication of DMD Exon 2
TS-000178 — A novel mouse model for testing exon skipping therapies for DMD disease has been generated at Nationwide Children’s Hospital. This mouse model carries a duplicated exon (exon2) in the DMD gene as compared to a point mutation in the most common mdx mouse model. This unique dystrophic mouse can serve as a preclinical testing model to test various therapies that mediate exon skipping.
  • College:
  • Inventors: Flanigan, Kevin; Vulin-Chaffiol, Adeline
  • Licensing Officer: Barkett, Margaret

Cmah-Deficient mdx Mice: A Better Mouse Model for Duchenne Muscular Dystrophy
TS-000127 — Putative cytidine monophosphate-N-acetylneuraminic acid hydroxylase-like protein is an enzyme that in humans is encoded by the CMAH gene. A new CMAH-Deficient mouse model for DMD-related research has been created. The CMAH-Deficient mouse model mimics the human disease better than the current standard model thus providing a model for DMD that facilitate translational research to be more relevant to issues affecting the human disease. Available through Jax Labs: Jax.org Stock #017929 Stage of Development: Development is Complete Potential Applications/Markets: It can be used to study development of drugs and biologics to treat Duchenne Muscular Dystrophy, therefore its primary application is in translational research. Opportunity / Seeking: Licensing
  • College:
  • Inventors: Martin, Paul
  • Licensing Officer: Eidahl, Jocelyn

Loading icon